论文部分内容阅读
目的:探究参麦注射液联合欣维宁治疗对急性心肌梗死介入后心脏结构和功能的影响。方法:选取我院2012-10-2015-12接收的经皮冠状动脉介入治疗的急性心肌梗死患者120例,按照随机数字法分为对照组60例和观察组60例,2组患者均进行皮冠状动脉介入治疗,对照组患者给予单一欣维宁治疗,观察组患者在此基础上联合参麦注射液治疗,比较2组患者的心脏结构和功能差异。结果:术后4h,观察组患者ST段回降(3.0±0.6)mm,明显高于对照组患者ST段回降(2.5±0.5)mm,差异有统计学意义(t=4.96,P=0.00)。术后7d,观察组患者ST段回降(3.2±0.8)mm,明显高于对照组患者ST段回降(2.7±0.4)mm,差异有统计学意义(t=4.33,P=0.00)。术后半年,观察组患者的左室射血分数(LVEF)、左室舒张末期容积(LVEDV)、收缩末期容积(LVESV)的心功能指标分别为明显优于对照组,差异有统计学意义(P<0.05)。术后半年内,观察组患者不良情况发生率为3.33%(2/60),明显低于对照组患者不良情况发生率18.33(11/60),差异有统计学意义(χ2=5.52,P=0.02)。结论:参麦注射液联合欣维宁治疗可以明显提高急性心肌梗死介入后患者的临床疗效,对其心脏结构和功能都有积极影响,患者的长期预后明显得到改善,故该联合治疗方案值得在临床推广。
Objective: To investigate the effect of Shenmai injection combined with Hinvynin on the cardiac structure and function after the intervention of acute myocardial infarction. Methods: A total of 120 acute myocardial infarction patients undergoing percutaneous coronary intervention were enrolled in our hospital from October 2012 to December 2015. The patients were divided into control group (60 cases) and observation group (60 cases) according to random number method. Patients in the control group were treated with single-dose fenvalerate. Patients in the observation group were treated with Shenmai injection on the basis of this study. The differences in cardiac structure and function between the two groups were compared. Results: At 4h postoperatively, the ST segment regression in the observation group (3.0 ± 0.6) mm was significantly higher than that in the control group (2.5 ± 0.5) mm, the difference was statistically significant (t = 4.96, P = 0.00 ). At 7 days after operation, the ST segment regression in the observation group (3.2 ± 0.8) mm was significantly higher than that in the control group (2.7 ± 0.4) mm, the difference was statistically significant (t = 4.33, P = 0.00). Six months after operation, the left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV) and end-systolic volume (LVESV) in the observation group were significantly better than those in the control group P <0.05). Six months after operation, the incidence of adverse events in the observation group was 3.33% (2/60), significantly lower than that in the control group (18.33%, 11/60) (χ2 = 5.52, P = 0.02). Conclusion: Shenmai injection combined with Shenweining can significantly improve the clinical efficacy of patients with acute myocardial infarction after intervention, which has a positive effect on cardiac structure and function, and the long-term prognosis of patients is obviously improved. Therefore, the combination therapy with Shenmai injection Clinical promotion.